Stable knockdown of JTB in HCC cells decreases cell apoptosis. by Yun-Peng Liu (108506)

Video_7_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Image_3_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.JPEG by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Image_2_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.JPEG by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Image_4_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.JPEG by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Video_3_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Video_6_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Video_1_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Video_2_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Video_4_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.WMV by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Image_1_Contribution of 5-HT2 Receptors to the Control of the Spinal Locomotor System in Intact Rats.JPEG by Henryk Majczyński (830716)

“…Little is known about the role of 5-HT receptors in the control of voluntary locomotion, so we administered inverse agonists of 5-HT₂ (Cyproheptadine; Cypr), 5-HT_2A neutral antagonist (Volinanserin; Volin), 5-HT_2C neutral antagonist (SB 242084), and 5-HT_2B/2C inverse agonist (SB 206553) receptors intrathecally in intact rats and monitored their effects on unrestrained locomotion. …”

Fig 5 - by Riffat Naz (12850637)

Effect of 2%, 4%, and 6% HQ cream on behavioral activities. by Huali Wu (349567)

“…<p>In open field test, a significant decrease was observed in the crossing (A) and rearing numbers (B) during 5minutes. …”

Effect of 2% HQ, 0.05% INN and 0.1% TAC on behavioral activities in C57BL/6 mice. by Huali Wu (349567)

“…<p>In open field test, a significant decrease was observed in the crossing (A) and rearing numbers (B) of INN and TAC group during 5minutes, whereas no change in the number of grooming episodes (C). …”

AnxA5 results in a tendency to decrease the monocyte endothelium interaction in a flow model. by Robert Stöhr (3583700)

Decrease in PP2A activity increases phosphorylation of p38MAPK, pMAPKAPK2 and Hsp27 in CD133+ cells. by Shih-Pei Lin (117914)

OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts. by S. Di Matteo (6260417)

“…After 4 weeks, when the tumor size was approximately 100 mm³ (T₀) mice were treated with OCA (0.03% w/w, 30 mg/kg) alone or combined with Cisplatin (2.4 mg/Kg in 100 μl) or Gemcitabine (1.05 mg/Kg in 100 μl) for 5 additional weeks. a) Results are expressed as percent increase in tumor volume at different time points. …”

Results of Analysis of Co-variance (ANCOVA) for change in parameter predicted by treatment group with pre-treatment value as a covariate. * p < 0.05; ** p < 0.01. by Lijuan Liu (136685)

Subjects:

Fig 5 - by Matthew C. Kochem (18476069)

Subjects:

HT1080 human sarcoma xenograft growth in CD-1 athymic mice and body weight comparison under therapy with intravenous (i.v.) tTF-NGR, tumor radiotherapy, and a combination of both t... by Caroline Brand (3448523)

“…<p>(A) Arrows show treatment intervention for tTF-NGR (1.5 mg/kg body weight (bw) x 5) or tumor radiotherapy (4.8 Gy x 2). …”